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Abstract
Synovial leukocyte apoptosis is inhibited in established
rheumatoid arthritis (RA). In contrast, high levels of leukocyte
apoptosis are seen in self-limiting crystal arthritis. The phase in
the development of RA at which the inhibition of leukocyte
apoptosis is first apparent, and the relationship between
leukocyte apoptosis in early RA and other early arthritides, has
not been defined. We measured synovial fluid leukocyte
apoptosis in very early arthritis and related this to clinical
outcome. Synovial fluid was obtained at presentation from 81
patients with synovitis of ≤ 3 months duration. The percentages
of apoptotic neutrophils and lymphocytes were assessed on
cytospin preparations. Patients were assigned to diagnostic
groups after 18 months follow-up. The relationship between
leukocyte apoptosis and patient outcome was assessed.
Patients with early RA had significantly lower levels of neutrophil
apoptosis than patients who developed non-RA persistent
arthritis and those with a resolving disease course. Similarly,
lymphocyte apoptosis was absent in patients with early RA
whereas it was seen in patients with other early arthritides. The
inhibition of synovial fluid leukocyte apoptosis in the earliest
clinically apparent phase of RA distinguishes this from other
early arthritides. The mechanisms for this inhibition may relate to
the high levels of anti-apoptotic cytokines found in the early
rheumatoid joint (e.g. IL-2, IL-4, IL-15 GMCSF, GCSF). It is likely
that this process contributes to an accumulation of leukocytes
in the early rheumatoid lesion and is involved in the development
of the microenvironment required for persistent RA.
Introduction
Inhibition of T-cell apoptosis in the synovium of patients with
established rheumatoid arthritis (RA) was first described in
1995 [1]. Subsequent work contrasted the virtually complete
inhibition of T-cell apoptosis in RA with high levels of T-cell
apoptosis in gout [2]. The phenotype of rheumatoid synovial T
cells (Bcl-XL 
high, Bcl-2low) demonstrated that their survival was
maintained by stromal mechanisms rather than by the common
γ-chain cytokines, and IFN-β was identified as a key fibroblast-
derived survival signal [3]. In addition to their effects on T cells,
both IFN-β and synovial fluid from RA patients delay neutrophil
apoptosis [4,5]. These observations led to the concept that
inhibition of leukocyte apoptosis, mediated by an expanded
fibroblast network in the rheumatoid joint, was an important
mechanism that maintains the leukocyte infiltrate in RA and
perpetuates disease [6].
We recently showed that patients with very early RA, within
the first 3 months of symptom onset, have a synovial fluid
cytokine profile that is distinct from those of patients with other
forms of very early synovitis and of patients with established
RA [7]. The synovial fluid of patients with very early RA is char-
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acterized by elevated levels of cytokines that are survival fac-
tors for T cells (IL-2, IL-4 and IL-15) and neutrophils
(granulocyte-macrophage colony-stimulating factor [GM-
CSF] and granulocyte colony-stimulating factor [G-CSF]). We
therefore sought to determine whether synovial fluid neutrophil
and lymphocyte apoptosis was inhibited in patients with very
early RA compared with patients with other very early inflam-
matory arthritides. We found that patients with very early RA
had significantly lower levels of neutrophil apoptosis than did
patients who developed non-RA persistent arthritis and those
with a resolving disease course. Similarly, lymphocyte apopto-
sis was absent in patients with early RA, whereas it was seen
in patients with other early arthritides. The inhibition of synovial
fluid leukocyte apoptosis in the earliest clinically apparent
phase of RA distinguishes this from other early arthritides.
Materials and methods
Patients
Patients were recruited through the rapid access clinic for
early inflammatory arthritis at City Hospital, Birmingham, UK.
Ethical permission was obtained and all patients gave written
informed consent. All patients had one or more swollen joints
and a symptom duration of 3 months or less. Patients with evi-
dence of previous inflammatory joint disease were excluded.
No patient had commenced a disease-modifying antirheu-
matic drug (DMARD) before initial assessment. Joints were
aspirated under either palpation or ultrasound guidance.
Patients were included in the study if adequate synovial fluid
was obtained by palpation or ultrasound-guided aspiration/lav-
age at initial assessment using a method described previously
[8]. Patients were subsequently assessed at 1, 2, 3, 6, 12 and
18 months. If joint effusions were present at follow-up assess-
ments, and if consent to a further arthrocentesis was obtained,
then these effusions were aspirated. Patients were assigned
to their final diagnostic groups at 18 months. Patients were
classified as having RA in accordance with the 1987 American
Rheumatism Association criteria [9], allowing criteria to be sat-
isfied cumulatively. Although the 1987 American Rheumatism
Association criteria have no exclusions, we excluded from the
RA category patients with alternative rheumatological diag-
noses explaining their inflammatory arthritis. Patients were
diagnosed with reactive arthritis, psoriatic arthritis, and a
number of miscellaneous conditions according to established
criteria.
Synovial fluid cytospin preparation and assessment
When synovial fluid was directly aspirated from the joint, the
number of leukocytes per millilitre of synovial fluid was counted
using a haemocytometer; a cell count measurement was not
performed when the sample was obtained by lavage. Synovial
fluid cytospins were made within 30 minutes of joint aspiration
or lavage [8]. The short sample processing time minimized the
potential for artefactual results due to apoptosis ex vivo. Slides
were air dried and stained with Diff-Quik (Dade Behring AG,
Düdingen, Switzerland). Cytospins were assessed by an
observer who was blinded to clinical details of the patients.
Leukocytes were identified on the basis of morphology. Apop-
totic cells were identified on the basis of a condensed or frag-
mented nucleus. Apoptotic neutrophils were distinguished
from apoptotic lymphocytes on the basis of acidophilic or
basophilic cytoplasmic staining (Figure 1). Up to 500 cells on
each slide were counted where possible. A minimum of 200
cells were counted or the sample was disregarded because of
lack of precision.
Statistical analysis
Categorical variables were compared using the χ2  test.
Numerical variables were compared between patient groups
using the Mann-Whitney test. Spearman's test was used to
assess the correlation between levels of neutrophil and lym-
phocyte apoptosis.
Results
Patients
Synovial fluid was obtained at presentation from 81 patients
with very early inflammatory arthritis. Characteristics of these
patients at presentation are shown in Table 1. Seventeen
patients developed RA. Of the 17 patients who developed a
Figure 1
Apoptotic lymphocytes and neutrophils in synovial fluid cytospin preparations from patients with very early inflammatory arthritis Apoptotic lymphocytes and neutrophils in synovial fluid cytospin preparations from patients with very early inflammatory arthritis. (a) An apoptotic 
lymphocyte (dashed arrow). (b) An apoptotic lymphocyte (dashed arrow) and apoptotic neutrophil (solid arrow). (c) Four apoptotic neutrophils (solid 
arrows).Available online http://arthritis-research.com/content/8/4/R120
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non-RA persistent inflammatory arthritis, the final diagnoses
were unclassified inflammatory arthritis (n = 9), psoriatic arthri-
tis (n = 3), arthritis related to connective tissue disease (n =
3), ulcerative colitis related arthritis (n = 1) and arthritis related
to Behçet's disease (n = 1). Of the 47 patients whose disease
resolved, the final diagnoses were unclassified inflammatory
arthritis (n = 25), gout (n = 9), pseudogout (n = 3), reactive
arthritis (n = 7), sarcoidosis (n = 1), ulcerative colitis related
arthritis (n = 1) and psoriatic arthritis (n = 1). One of the
patients labelled as having an unclassified resolving inflamma-
tory arthritis fulfilled classification criteria for RA at presenta-
tion. This patient received an intramuscular injection of steroid
after 10 weeks of symptoms, following which the patient
remained in remission off therapy throughout follow-up.
Patients whose disease progressed to RA were significantly
older than patients who developed non-RA persistent synovitis
or patients whose disease resolved. Patients whose disease
resolved had a significantly shorter duration of symptoms at
presentation compared with patients in the other two groups.
The following joints were aspirated at clinical presentation:
knee (n = 60), ankle (n = 11), metacarpophalyngeal joint (n =
4), proximal interphalyngeal joint (n = 2), shoulder joint (n = 1),
elbow joint (n = 1), wrist (n = 1) and talonavicular joint (n = 1).
The knee was aspirated in 10 (59%) of the patients who devel-
oped RA, 15 (83%) of the patients who developed a non-RA
persistent arthritis and 36 (76%) of the patients with resolving
disease. There was no significant difference between the
groups in terms of the numbers of patients who had the knee
or another joint aspirated (χ2 test; P = 0.22).
Synovial fluid leukocyte apoptosis at clinical 
presentation
Levels of synovial fluid neutrophil apoptosis were available for
71 patients at their initial visit. For the remaining 10 patients
the number of neutrophils was too low to quantify the percent-
age of cells that were apoptotic. Sixteen of the 71 patients
developed RA, 15 developed non-RA persistent synovitis and
40 had resolving disease. There was a significant difference in
the percentage of apoptotic synovial fluid neutrophils between
patients who developed RA and patients in the other two
groups (RA versus non-RA persistent synovitis, P = 0.02; RA
versus resolving synovitis, P = 0.003; Figure 2a). The median
numbers of neutrophils per millilitre of synovial fluid in the initial
samples of patients in the three groups were as follows: 2.5 ×
106 (interquartile range [IQR] 0.2–6.0 × 106) for patients with
RA; 7.1 × 106 (IQR 3.1–22.6 × 106) for patients with non-RA
persistent synovitis; 3.9 × 106 (IQR 0.04–11.4 × 106) for
patients with resolving synovitis. Patients with RA had a lower
absolute number of apoptotic neutrophils per millilitre in their
initial synovial fluid samples (0.02 × 106 [IQR 0.003-0.09 ×
106]) than did patients with non-RA persistent synovitis (0.14
× 106 [IQR 0.02–0.99 × 106]; P = 0.046) or patients with
resolving synovitis (0.14 × 106 [IQR 0.02–0.54 × 106]; P =
0.023).
Levels of synovial fluid lymphocyte apoptosis were available
from synovial fluid cytospin preparations of 75 patients at their
initial visit. For the remaining six patients the number of lym-
phocytes in the synovial fluid sample was too low to quantify
the percentage of cells that were apoptotic. Sixteen of these
patients developed RA, 15 developed non-RA persistent syn-
ovitis and 44 had resolving disease. There was a trend toward
a lower level of lymphocyte apoptosis in the initial samples of
patients with very early synovitis that developed into RA com-
pared with initial samples of patients whose disease resolved,
but this did not achieve statistical significance (Figure 2b). The
median numbers of lymphocytes per millilitre of synovial fluid in
the initial samples of patients in the three groups were as fol-
lows: 0.9 × 106 (IQR 0.1–1.4 × 106) for patients with RA; 1.1
× 106 (IQR 0.8–5.0 × 106) for patients with non-RA-persistent
synovitis; and 0.5 × 106 (IQR 0.1–1.6 × 106) for patients with
resolving synovitis. There was no significant difference
between the absolute numbers of apoptotic lymphocytes per
millilitre in the initial synovial fluid samples from patients in the
three groups.
Table 1
Baseline characteristics of patients with very early inflammatory arthritis
Characteristic RA Non-RA P
Persistent Resolving
n 17 17 47
Female (n [%]) 9 (53%) 6 (35%) 24 (51%) NSa
Age, years (median [IQR]) 64 (58–73) 37 (25–58) 41 (29–64) RA versus non-RA persistent: P = 0.001b; RA 
versus resolving: P = 0.0008b
Symptom duration (weeks; median [IQR]) 7 (5–9) 7 (2.5–11.5) 3 (1–5) RA versus resolving P < 0.0001b
CRP (median [IQR]) 32 (18–53) 62 (31–95) 32 (10–96) NSb
RF positive (n [%]) 13 (76%) 1 (6%) 5 (10.6%)
aχ2 test. bMann-Whitney test. CRP, C-reactive protein; IQR, interquartile range; NS, not significant; RA, rheumatoid arthritis; RF, rheumatoid factor.Arthritis Research & Therapy    Vol 8 No 4    Raza et al.
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Only an occasional apoptotic macrophage was seen, and
there were no differences between groups in terms of apop-
totic macrophages.
Longitudinal assessment of synovial fluid leukocyte 
apoptosis
Several patients underwent repeat joint aspiration during their
follow-up. Results for synovial neutrophil apoptosis from fol-
low-up joint aspirations were available for 16 synovial fluid
samples from 10 RA patients, 25 samples from 11 of the
patients with non-RA persistent synovitis, and 17 samples
from 11 of the patients with resolving synovitis. The number of
weeks after symptom onset at which these follow-up samples
were collected is shown in Table 2. More neutrophil apoptosis
was seen in a follow-up sample than at initial presentation in
two of the 10 RA patients, six of the 11 patients with non-RA
persistent synovitis and four of the 11 patients with resolving
synovitis. Prior therapy with a DMARD or parenteral steroid
was not associated with enhanced levels of synovial neutrophil
apoptosis at subsequent follow up (Table 2). The maximum
percentage of synovial neutrophil apoptosis observed for each
patient is shown in Figure 2c. The maximum level of synovial
fluid neutrophil apoptosis was significantly lower in patients
with RA than in patients with non-RA persistent synovitis (P =
0.0004) or in patients with resolving synovitis (P = 0.002).
Results for synovial lymphocyte apoptosis from follow-up joint
aspirations were available for 12 synovial fluid samples from
seven RA patients, 26 samples from 11 of the patients with
non-RA persistent synovitis, and 21 samples from 13 of the
patients with resolving synovitis. The number of weeks after
symptom onset at which these follow-up samples were col-
lected is shown in Table 2. More lymphocyte apoptosis was
seen in a follow-up sample than at initial presentation in two of
the seven RA patients, four of the 11 patients with non-RA per-
sistent synovitis, and seven of the 13 patients with resolving
synovitis. Prior therapy with a DMARD or parenteral steroid
was not associated with enhanced levels of synovial lym-
phocyte apoptosis at subsequent follow-up (Table 2). The
maximum percentage of synovial lymphocyte apoptosis
observed for each patient is shown in Figure 2d. There was a
trend toward patients with RA having less synovial lymphocyte
apoptosis than patients with non-RA persistent synovitis (P =
0.09) or patients with resolving synovitis (P  = 0.054).
Levels of synovial fluid neutrophil and lymphocyte apoptosis in
initial and subsequent samples in patients who developed
either RA or non-RA persistent inflammatory arthritis are
shown in Figure 2e and 2f. The highest levels of leukocyte
apoptosis in patients who developed non-RA persistent
inflammatory arthritis were seen within the first 20 weeks of
symptom onset. Only one patient who developed RA had sig-
nificant levels of neutrophil apoptosis (12%) and lymphocyte
apoptosis (1.5%) in a synovial fluid sample obtained after 10
weeks of symptoms. Lymphocyte and neutrophil apoptosis
were virtually absent from all other synovial fluid samples from
RA patients, irrespective of disease duration.
There was a statistically significant correlation between the
levels of neutrophil and lymphocyte apoptosis in the synovial
fluid samples (data not shown; Spearman r  = 0.26; P  =
0.004).
Discussion
The early phase of RA, within 3 months of symptom onset, was
characterized by very low levels of apoptotic leukocytes within
the synovial compartment. During this phase of disease,
patients with very early inflammatory arthritis who eventually
developed RA had a significantly lower level of synovial fluid
neutrophil apoptosis than did patients whose disease
resolved. In addition, synovial fluid lymphocyte apoptosis was
rarely observed in very early RA. There was a trend toward a
higher level of lymphocyte apoptosis in patients with resolving
disease compared with those who had very early RA. The inhi-
bition of synovial fluid leukocyte apoptosis that characterizes
established RA is thus also apparent in the earliest clinically
apparent phase of disease. It is likely that this process contrib-
utes to the accumulation of leukocytes in the early rheumatoid
lesion and is important in the development of the microenviron-
ment that characterizes established RA. Follow-up assess-
ments over the first 18 months of disease revealed that
leukocyte apoptosis was inhibited at all time points in patients
who developed RA, despite the fact that a proportion of
patients had been treated, before the follow-up arthrocentesis,
with antirheumatic drugs that have been reported to induce
leukocyte apoptosis [10,11].
The mechanisms underlying the inhibition of leukocyte apopto-
sis in patients with very early RA remain undefined. In addition
to IFN-β, other mechanisms for the rescue of leukocytes from
apoptosis may operate in established RA. Exposure of CD4+
T cells to stromal cell-derived factor-1α(SDF-1α (produced by
synovial fibroblasts)) renders T cells less susceptible to apop-
tosis induced by anti-CD3 stimulation [12] and to cytokine
deprivation induced apoptosis [13]. In Crohn's disease and
experimental colitis, a role has been suggested for IL-6 trans
signaling in mediating the inhibition of apoptosis in lamina pro-
pria T cells [14]. The contributions of such mechanisms to the
type 1 interferon mediated T-cell rescue that operates in the
rheumatoid joint is, at present, unclear. However, it is likely that
the high levels of common γ-chain cytokines (IL-2, IL-4 and IL-
15) and of G-CSF and GM-CSF that we recently reported in
the very early rheumatoid lesion [7] play a role in lymphocyte
and neutrophil survival in this phase of disease. Although these
factors are not present in the joints of patients who progress
to non-RA persistent disease, synovial leukocyte apoptosis
was partially inhibited in these patients. Therefore, other fac-
tors are likely to contribute to leukocyte survival in the very
early phase of disease that eventually persists. Macrophage-
derived IFN-α is a potent survival factor for T cells and neu-Available online http://arthritis-research.com/content/8/4/R120
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trophils [3,15]. Synovial macrophages may thus contribute to
the inhibition of leukocyte apoptosis that is seen in early
arthritides that progress to persistence.
The low level of leukocyte apoptosis in the initial samples of
some patients whose disease eventually resolved was intrigu-
ing. A study of lymphocyte apoptosis during the course of a
delayed-type hypersensitivity response [16] showed that lev-
els of lymphocyte apoptosis change as the lesion develops,
being absent during the generation of the response and
present during its resolution. In patients with self-limiting
inflammatory lesions, the level of lymphocyte apoptosis thus
appears to depend on the stage of the process at which the
lesion is sampled. Our results suggest a transient inhibition of
lymphocyte apoptosis at early stages of the disease process
in some patients with a resolving inflammatory arthritis. Poten-
tial mechanisms for this include the transient presence of sol-
uble survival factors such as IFN-α.
Figure 2
Synovial fluid neutrophil and lymphocyte apoptosis in patients with very early inflammatory arthritis Synovial fluid neutrophil and lymphocyte apoptosis in patients with very early inflammatory arthritis. (a) Synovial fluid neutrophil apoptosis at clinical 
presentation in patients with very early inflammatory arthritis divided according to outcome. (b) Synovial fluid lymphocyte apoptosis at clinical pres-
entation in patients with very early inflammatory arthritis divided according to outcome. (c) Maximum synovial fluid neutrophil apoptosis observed in 
each patient with very early inflammatory arthritis; patients divided according to outcome. (d) Maximum synovial fluid lymphocyte apoptosis in each 
patient with very early inflammatory arthritis; patients divided according to outcome. (e) Synovial fluid neutrophil apoptosis over time in all samples 
obtained from patients with very early inflammatory arthritis that eventually persisted divided according to outcome (open circles = non-RA persistent 
synovitis; closed circles = RA). (f) Synovial fluid lymphocyte apoptosis over time in all samples obtained from patients with very early inflammatory 
arthritis that eventually persisted divided according to outcome (open circles = non-RA persistent synovitis; closed circles = RA). Comparisons were 
made using the Mann-Whitney test. RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 8 No 4    Raza et al.
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In this study patients who developed RA were older than
patients with other early arthritides. It has previously been
reported that neutrophils from older individuals are more sus-
ceptible to spontaneous apoptosis than are neutrophils from
younger persons, and that rescue from spontaneous and Fas-
induced apoptosis by cytokines such as GM-CSF and G-CSF
is less effective in neutrophils from older individuals than in
those from younger ones [17,18]. In addition, the rate of spon-
taneous lymphocyte apoptosis is enhanced in elderly individu-
als compared with younger individuals [19,20]. Consequently,
it is unlikely that the reduced leukocyte apoptosis observed in
RA patients is a feature of their greater age compared with
other early arthritis patients.
Conclusion
Synovial fluid leukocyte apoptosis is inhibited during the earli-
est clinically apparent phase of RA. This contrasts with other
early arthritides, in which significantly higher levels of neu-
trophil apoptosis are seen in the early lesion. The inhibition of
leukocyte apoptosis in the joints of patients with RA, within the
first 12 weeks of symptoms, and the presence of apoptosis in
the joints of patients whose disease resolves suggest that
therapies that induce leukocyte apoptosis may be useful within
the first few weeks of symptoms in patients at high risk for
development of RA.
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Table 2
Details of patients with very early inflammatory arthritis from whom follow-up synovial fluid samples were obtained in which 
neutrophil or lymphocyte apoptosis could be quantified
RA Non-RA
Persistent Resolving
Neutrophil Lymphocyte Neutrophil Lymphocyte Neutrophil Lymphocyte
Number of patients from whom analyzable follow-up 
samples were available
10 7 11 11 11 13
Number of analyzable follow-up samples 16 12 25 26 17 21
Number of weeks after symptom onset when follow-up 
samples were collected (median [IQR])
19 (15–38) 18 (13–39) 26 (14–46) 28 (14–46) 13 (9–28) 14 (9–22)
Number of patients in whom more apoptosis was seen 
in a follow-up sample than in the initial sample
226447
Treatment received prior to follow-up joint aspiration where more apoptosis was seen at follow-up
N i l 011001
Parenteral steroid 0 0 1 1 4 6
D M A R D 002100
Parenteral steroid + DMARD 2 1 2 2 0 0
Treatment received prior to follow-up joint aspiration where no more apoptosis was seen at follow-up
N i l 200032
Parenteral steroid 1 0 4 6 4 4
D M A R D 000000
Parenteral steroid + DMARD 5 5 1 1 0 0
DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/8/4/R120
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